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Mark F. Conrad, MD, MSSc, Michael T. Watkins, MD, Christopher J. Kwolek, MD,
Glenn M. LaMuraglia, MD, and Richard P. Cambria, MD, Boston, Mass
Objective: Patients with severe chronic kidney disease (CKD) and peripheral vascular disease are at increased risk of major
adverse limb events (MALEs) and death; however, patients with end-stage renal disease have been excluded in current
objective performance goals. We evaluated the effect of severe (class 4 and 5) CKD on outcomes after infrainguinal
endovascular arterial interventions.
Methods: All primary peripheral vascular interventions (PVIs) performed at a single institution (January 2002 through
December 2009) were included. End points were deﬁned by Society for Vascular Surgery objective performance goals for
critical limb ischemia (CLI), which include all-cause mortality, reintervention, and composite end points of death or
amputation and MALEs (reintervention or amputation). Univariate and multivariable analysis was used to examine the
effect of severe CKD on study end points.
Results: A total of 879 PVIs were performed, with severe CKD in 125 (14%). Severe CKD patients were signiﬁcantly (P <
.05) more likely to have diabetes (64% vs 46%), CLI (72% vs 11%), and need a multilevel PVI (34% vs 19%) or tibial
intervention (35% vs 20%) compared with the remainder of the cohort. Distribution of TransAtlantic Inter-Society
Consensus C and D lesions were similar (19% severe CKD vs 15%; P [ .2). Severe CKD predicted perioperative (30-
day) reintervention (odds ratio [OR], 2.3; 95% conﬁdence interval [CI], 1.5-4; P [ .05), amputation or death (OR,
3.1; 95% CI, 1.1-9; P [ .04), and MALEs (OR, 2.8; 95% CI, 1.3-6.1; P [ .04), which was independent of CLI in
multivariable regression analysis. On Kaplan-Meier analysis, severe CKD was signiﬁcantly (log-rank P < .05) associated
with death (31% 6 4% vs 7% 6 1%), amputation (14% 6 3% vs 3% 6 1%), and MALEs (40% 6 5% vs 26% 6 2%) at 1 year.
Freedom from reintervention was similar at 1 year (70% 6 5% severe CKD vs 75% 6 2%; P [ .23). Risk-adjusted (age,
CLI, diabetes, coronary artery disease) Cox proportional hazards regression showed that severe CKD increased the risk of
late mortality (hazard ratio [HR], 2.4; 95% CI, 1.8-3.2; P < .01), amputation (HR, 2.1; 95% CI, 1.1-3.9; P[ .02), and
death or amputation (HR, 1.8; 95% CI, 1.3-2.4; P[ .04), without increasing the risk of late reinterventions or MALEs.
Conclusions: CKD independently predicts early and late adverse events after a PVI, in particular, excessive mortality.
CKD should ﬁgure prominently in clinical decision making for patients with peripheral vascular disease. (J Vasc Surg
2014;59:368-75.)Likely related to minimal morbidity and a lower
threshold to recommend intervention, there has been an
exponential growth in peripheral vascular interventions
(PVIs),1,2 yet performance standards for PVIs are lacking.
The Society for Vascular Surgery (SVS) recently established
objective performance goals (OPGs) for critical limb
ischemia (CLI) as benchmarks for clinical outcomes in
PVI trials for new devices.3 These OPGs were derived
based on expected outcomes for lower extremity arterialthe Division of Vascular and Endovascular Surgery, Massachusetts
eneral Hospital, Harvard Medical School.
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contemporary surgical bypass trials (Edifoligide for the
Prevention of Infrainguinal Vein Graft Failure [PREVENT
III],4 CIRCULASE,5 and Bypass vs Angioplasty in
Severe Ischemia of the Leg [BASIL]6). Although initially
developed as benchmarks for single-arm endovascular
device trials, these OPGs have and will continue to serve
as important clinical quality measures for patients under-
going lower extremity revascularizations, whether open
or endovascular.
Several high-risk factors were identiﬁed by the OPG
document. These high-risk clinical (age >80 years and
tissue loss), anatomic (distal to below-knee popliteal
outﬂow), and conduit (lack of adequate length or diam-
eter [>3 mm] saphenous vein) features were associated
with reduced limb salvage or survival and therefore merit
careful consideration in clinical practice. However, the
SVS OPGs excluded patients with end-stage renal disease
(ESRD), which previous investigators have shown confers
a signiﬁcant survival disadvantage in patients with periph-
eral vascular disease (PVD) and associated comorbid-
ities.7-11 The goal of this study therefore was to evaluate
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operative and late outcomes after infrainguinal PVIs.
METHODS
Study design. This is a retrospective cohort study of
patients who underwent infrainguinal PVIs for PVD at
Massachusetts General Hospital from January 2002
through December 2009. The study outcome measures
included perioperative (30-day) and late death as the
primary end point. Secondary end points were amputation,
reintervention, and the composite OPG end points of
death or amputation and major adverse limb events
(MALEs) of reintervention or amputation. These end
points were chosen because the OPG investigators identi-
ﬁed them as key outcome measures to ensure durable
clinical efﬁcacy.
The composite end points emphasize consideration of
limb-speciﬁc and survival-related end points after PVIs.
Amputation was deﬁned as a below-knee or above-knee
amputation (loss of foot amputations) and therefore
excluded isolated toe amputations or partial foot amputa-
tions. Reinterventions were deﬁned as any open or endo-
vascular reintervention in the index limb independent of
the lesion treated. This deﬁnition varies from the OPG
guidelines, which deﬁne reinterventions as speciﬁc open
procedures for graft failure. Therefore, the threshold for
deﬁning a MALE by way of reintervention was markedly
lower in our study compared with the OPG guidelines,
thus increasing the risk of MALEs in our cohort.
Study population. Eligibility criteria for this study
were any adult patient undergoing primary percutaneous
intervention for infrainguinal PVD; patients undergoing
aortoiliac interventions were excluded. The speciﬁcs of
the percutaneous intervention regarding primary angio-
plasty or angioplasty and stenting were at the discretion
of the attending vascular surgeon or cardiologist. Patients
with clinically and radiologically conﬁrmed PVD were
enrolled and consented before the procedure.
Demographics, clinical features, and medical history
details recorded included indication for procedure (claudi-
cation, rest pain, or tissue loss), extent of arterial disease
(femoral-popliteal disease, tibial disease), medications
(Coumadin [Bristol-Myers Squibb, Princeton, NJ], lipid-
lowering agents, b-blockers) smoking history, hyperten-
sion, diabetes, and history of coronary artery disease
(CAD). CLI was deﬁned by indication as rest pain or tissue
loss (ulcer or gangrene) derived from patient presentation
or from operative notes. The extent of PVD was assessed
angiographically at the time of the intervention and catego-
rized using TransAtlantic Inter-Society Consensus (TASC)
Class12 A (focal disease) to D (extensive). The technical
procedural details were recorded.
The exposure variable of interest, severe CKD, deﬁned
as patients with CKD class 4 or 5, was derived from a
preliminary sensitivity analysis. The estimated glomerular
ﬁltration rate (eGFR) was calculated for each patient using
the Modiﬁed Diet in Renal Disease (MDRD) equation
[GFR ¼ 186.3  serum creatinine1.154  age0.203  1.212(if black)  0.742 (if female)]. Patients were assigned to
standard CKD classes13 based on eGFR values: CKD 1,
GFR >90 mL/min/1.73 m2; CKD 2 (mild), GFR of 60
to 89 mL/min/1.73 m2; CKD 3 (moderate), GFR of 30
to 59 mL/min/1.73 m2; CKD 4 (severe), GFR of 15 to
29 mL/min/1.73 m2; and CKD 5 (kidney failure),
GFR <15 mL/min/1.73 m2.
Baseline preoperative creatinine, age, sex, and race
were used to calculated eGFR and establish a CKD class
for all patients in our study. Patients were then stratiﬁed,
based on preliminary analysis, into two groups for compar-
ative analysis: those with severe CKD (class 4 and 5;
eGFR <30 mL/min/1.73 m2) vs those with lesser degrees
of CKD (eGFR $30 mL/min/1.73 m2).
Statistical analysis. Univariate analysis was performed
to compare baseline clinical and demographic features,
operative details, and perioperative outcomes. Continuous
variables are presented as mean value and 95% conﬁdence
intervals (CIs). Discrete variables are presented as number
of events and population percentages. Differences between
the CKD categories were evaluated using the Fisher exact
test for binomial outcome variables and the c2 test for
ordinal data. A Kaplan-Meier product limit estimator
curve was plotted to compare survival functions between
patients with severe CKD and those without severe CKD.
Observations were censored if patients survived or did not
require amputation at the last documented follow-up.
A multivariable risk-adjusted Cox proportional hazards
model was used to obtain hazard ratios (HRs), 95% CIs,
and P values for primary and secondary end points. The
proportional hazards assumption was assessed using
Schoenfeld residuals. Statistical analysis was performed
with SAS 9.2 software (SAS Institute, Cary, NC), and
signiﬁcance was deﬁned as a two-tailed P value of <.05.
RESULTS
We identiﬁed 879 patients (54% male), who were
a mean 6 standard deviation age of 71 6 11 years. CKD
was mild or normal (class 1 or 2) in 48% of the patients,
moderate (class 3) in 38%, and severe (class 4 or 5) in
14%. Sensitivity analysis to evaluate for a dose-dependent
effect of CKD showed an incremental increase in outcome
measures for patients with severe CKD compared with
patients with normal renal function, mild CKD, or
moderate CKD (Fig 1); therefore, severe CKD was chosen
as the exposure variable for our study.
Baseline characteristics of patients with and without
severe CKD are presented in Table I. By univariate analysis,
severe CKD was associated with a signiﬁcantly (P < .05)
higher proportion of diabetes, insulin use, and hemodialysis
dependence, and patients were more likely to present with
CLI (Table I). Patients with severe CKD had a similar
distribution of SVS high-risk criteria (age >80 years and
tissue loss) compared with patients without severe CKD
(14% severe CKD vs 11%; P ¼ .26).
Procedural details are presented in Table II. Patients
with severe CKD were more likely to undergo multilevel
interventions, which were driven by an increased frequency
Fig 1. Kaplan-Meier curves plot long-term survival in patients with mild, moderate, or severe chronic kidney disease
(CKD) undergoing peripheral vascular interventions (PVIs).
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ventions. Distribution of more extensive vascular disease
(TASC C and D) was similar in the two groups (19% severe
CKD vs 15%; P ¼ .2). Multivariable logistic regression
modeling showed that severe CKD was only an indepen-
dent predictor of perioperative reintervention, with no
associated increase in risk of death or major amputation
(Table III). All models adjusted for patient age, CLI, and
diabetes, and the mortality model also controlled for CAD.
At a mean follow-up of 32 6 21 months, 24% of the
patients had died, and 5% required major amputation.
Survival after percutaneous intervention was 90% 6 1%
at 1 year and 65% 6 2% at 5 years in all patients under-
going PVIs. Severe CKD was associated with statistically
(P < .001) lower late survival (Fig 2) yet higher major
amputation (Fig 3). CKD was not associated (P ¼ .23)
with increased late reinterventions at 1 year (70% 6 5%
severe CKD vs 75% 6 2%) and 3 years (62% 6 5% vs69%6 2%). Patients with severe CKD had a lower freedom
from the composite outcome of death or amputation (P <
.001) at 1 year (69% 6 4% vs 91% 6 1%) and 3 years
(54% 6 5% vs 76% 6 2%). Similarly, freedom from the
composite OPG end point of a MALE was lower (P ¼
.002) in patients with severe CKD at 1 year (60% 6 5%
vs 74% 6 2%) and 3 years (53% 6 6% vs 63 6 2%).
Multivariable Cox proportional hazards regression
models were performed to evaluate the risk-adjusted effect
of severe CKD on late outcomes. The risk-adjusted hazard
for death, adjusting for confounding by age, CLI, diabetes,
and CAD, was signiﬁcantly increased in patients with severe
CKD (HR, 2.4; 95% CI, 1.8-3.2; P < .001). Severe CKD
independently increased the risk of late amputation (HR,
2.1; 95% CI, 1.1-3.9; P ¼ .02) when controlling for CLI
and diabetes. Severe CKD was not a predictor of late rein-
tervention risk. For the composite OPG end points, severe
CKD predicted increased risk of death or amputation










Multilevel, % 33.6 19.3 .0003
Femoral-popliteal, % 97.6 98.8 .287
Tibial, % 35.2 19.6 <.001
TASC C or D, % 19.4 15 .218
CKD,Chronic kidney disease;TASC,TransAtlantic Inter-SocietyConsensus.









Age, mean 6 SD, years 71.9 6 10 70.7 6 11 NS
Male sex, % 63.2 63.6 .93
Hypertension, % 95.1 94.4 .76
Diabetes, % 63.7 46.2 .003
Insulin, % 39.8 19.9 <.001
CAD, % 68.9 63.2 .23
Hemodialysis, % 54 NA <.001
Current smoker, % 9.6 21 .0038
Hypercholesterolemia, % 76.7 84 .048
CLI, % 71.8 29 <.001
SVS high risk,a % 14.4 11.1 .29
Coumadin,b % 74 83 .01
CAD, Coronary artery disease; CKD, chronic kidney disease; CLI, critical
limb ischemia; NA, not applicable; NS, not signiﬁcant; SD, standard devi-
ation; SVS, Society for Vascular Surgery.
aDeﬁned as age >80 years and CLI.
bBristol-Myers Squibb, Princeton, NJ.
Table III. Independent effect of severe chronic kidney
disease (CKD) on 30-day outcomes
Outcome OR (95% CI) P
Death 2.3 (0.6-9.3) .24
Reintervention 2.3 (1.01-5.4) .05a
Amputation 3.3 (0.7-15.1) .12
Amputation or death 3.1 (1.1-9) .04a
MALE (amputation or reintervention) 2.8 (1.3-6.1) .04a
CI, Conﬁdence interval; MALE, major adverse limb event; OR, odds ratio.
aStatistically signiﬁcant.
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risk of MALEs largely related to the absence of effect on late
reinterventions. Schoenfeld residuals for severe CKD resulted
in nonsigniﬁcant (>0.05) residual values for severe CKD in
each of the models, validating the proportional hazards
assumption inherent to Cox hazards regression modeling.DISCUSSION
This is the largest study to date evaluating the effect of
severe CKD on outcomes after PVIs for infrainguinal PVD.
Our ﬁndings are notable for the fact that severe CKD is an
important independent predictor of early and late adverse
events after PVIs. Our study showed no independent
effect of severe CKD on perioperative death or major
amputation. This ﬁnding is consistent with the literature,
as others have shown perioperative amputation and death
rates are similar in patients with and without ESRD under-
going lower extremity bypass.7-9 Owens et al9 showed no
signiﬁcant impact of CKD on perioperative mortality or
amputation rates in 456 patients treated with open revascu-
larization for CLI. Although our ﬁndings reﬂect the less
invasive nature of and the lower periprocedural risk of
PVI, Willenberg et al,10 in an analysis of 218 PVI proce-
dures performed in patients presenting with CLI, similarly
reported that severe CKD did not increase perioperative
death.
We observed an increased risk of early postoperative
reinterventions in patients with severe CKD. This may be
related to a higher disease burden, as evidenced by our
observation that patients with severe CKD were more likely
to require multilevel interventions as well as tibial interven-
tions. Several recent reports on tibial interventions in
patients with CLI and ESRD have noted diffuse calciﬁc
disease with pedal vessel involvement in almost two-
thirds of such patients.14,15 The smaller vessel size of tibial
vessels, more advanced disease at presentation in patients
with severe CKD, and an increase in vascular calcium depo-
sition associated with advanced kidney disease may have
contributed to the increased risk of intervention failure in
our series. Especially in our own practice, in which primary
balloon angioplasty of vascular lesions is the method of
choice and elective stenting (eg, for recalcitrant lesions,
residual stenosis >30%, or ﬂow-limiting dissections) is
only performed inw20% of patients.16 Our selective stent-
ing approach may have contributed to the increased need
for reintervention in patients with severe CKD in the
setting of heavily calciﬁed plaques or more diffuse disease
at presentation requiring further intervention. Whether
related to our practices, which can be overcome with
primary stenting, or intrinsic patient biology, our ﬁndings
suggest aggressive postoperative surveillance and medical
management in severe CKD patients.
In our cohort, severe CKD conferred a higher long-
term risk of major amputation without the additional risk
of reintervention beyond the perioperative period. Several
reports noted increased late amputation risk in patients
with advanced kidney disease.7-9,17 Owens et al9 observed
that 8% of patients with class 1 to 4 CKD required late
amputations, whereas patients with ESRD (CKD 5) had
a statistically higher amputation rate at 23%. These investi-
gators9 noted that almost half of the ESRD patients under-
went amputation despite patent bypass grafts. These
ﬁnding may be related to more advanced disease at presen-
tation, as we found severe CKD patients were more likely
Fig 2. Kaplan-Meier curves plot long-term survival by severity of chronic kidney disease (CKD).
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tissue loss has been shown to increase the risk of major
amputation. Ramdev et al,7 in the largest single-center
series of open surgical bypass in patients with ESRD, re-
ported that 52% of patients required amputation despite
patent grafts owing mainly to extensive heel gangrene
and tissue loss.
Recent data from the Vascular Study Group of New
England have further corroborated the independent effect
of ESRD on clinical failure and late limb events.18,19 These
data suggest that unmeasured factors, such as malnutrition,
poor wound healing, immunologic dysfunction, vasomotor
dysregulation, diffuse calciﬁc disease, advanced tissue loss,
or other CKD-related factors, contribute to clinical failure
and warrant further study.
Another possibility to consider is that none of these
studies, including our own, had consistent and objective
follow-up protocols. We do not have a formal institutional
follow-up or decision analysis algorithm incorporating
hemodynamic measurements, duplex evaluation, and clin-
ical examination ﬁndings, as suggested by clinical practice
guidelines. Patients therefore underwent reintervention or
amputation at the discretion of the operating surgeon.
Clinical failure may have resulted from a lack ofhemodynamic improvement or loss of patency in addition
to the factors noted above and would not have been
detected given limitations in our follow-up. Use of a strin-
gent objective follow-up protocols may have may have led
to increased reintervention, reduced long-term amputation
risk, and most importantly, better discerned the cause of
clinical failure and warrants further study in this population.
The most striking disadvantage of severe CKD is that
of increased late death. The National Kidney Foundation
estimates the median survival of ESRD patients is
2.5 years.20 Our data suggest a similar late survival, with
a median survival of 2.6 years in patients with severe
CKD. Similar to our ﬁndings, patients with class 4 and 5
CKD had reduced late survival in two large cohorts under-
going open21 or endovascular revascularization.10 Many
groups have reported poor long-term survival in dialysis-
dependent patients after lower extremity bypass.7-9,21,22 A
recent meta-analysis23 of infrainguinal bypass in patients
with ESRD pooled outcomes from 28 studies. The pooled
data included 1027 patients with a 5-year survival rate of
28%, similar to our survival of 24%. Yet others have re-
ported a markedly worse survival. Ramdev et al7 reported
a dismal 5-year survival rate of 5% compared with 24% in
our series. This likely represents patient selection, because
Fig 3. Kaplan-Meier curves plot freedom from amputation by severity of chronic kidney disease (CKD). No events
were observed >2 years.
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tissue loss (100% vs 56%), and diabetes (92% vs 48%),
whereas our cohort also included patients with claudication.
It is clear from the literature and our data that severe
CKD confers a signiﬁcant survival disadvantage to patients.
In contrast, contemporary series of patients without kidney
disease treated for PVD report 5-year survival rates of
w50% to 60%.6,21,24 Results from the BASIL trial suggest
that in patients with reduced long-term survival
(w2 years), bypass-ﬁrst and angioplasty-ﬁrst approaches
to CLI are equally efﬁcacious. Recent survival modeling25
based on BASIL trial data suggested that elevated creati-
nine, tissue loss, older age (>70 years), and poor runoff
were independent predictors of death #2 years of random-
ization. In light of these ﬁndings and the markedly reduced
survival in patients with severe CKD, it is prudent to
suggest that the long-term survival of severe CKD patients
may be prohibitive to lower extremity revascularization by
any modality in very high-risk patients. Whether an open or
endovascular approach is considered in lower-risk patients
requires further study; however, clinical decisions to inter-
vene must take into consideration the higher risk of early
reintervention for PVI and the reduced late mortality andhigher long-term limb loss independent of revasculariza-
tion strategy.
Several limitations of our study need consideration, the
ﬁrst of which relates to our study design. We chose to
stratify patients into groups with and without severe
CKD. Given the graded effect seen of worsening CKD
on cardiovascular mortality,11 evaluating outcomes in all
CKD classes would have been ideal. Our study was under-
powered to detect a difference in ﬁve CKD strata. We
therefore deﬁned our threshold of severe CKD based on
preliminary analyses that suggested long-term outcomes
were reduced only in class 4 and 5 CKD. In the largest
publication to date on the effect of CKD after lower
extremity bypass, O’Hare et al17 stratiﬁed Veterans
Affairs-National Surgical Quality Improvement Program
patients by severity of CKD into mild, moderate, severe,
and ESRD. In their study of 9932 patients undergoing
lower extremity arterial revascularization, multivariable
analysis supported a threshold severity because only
ESRD (CKD 5) conferred an independent risk of late
amputation. This was also suggested by Owens et al,18
who found that an eGFR threshold of <30 mL/min/
1.73 m2 (class 4 and 5 CKD) deﬁned patients at highest
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gested similar long-term outcomes in patients with
normal/mild (class 1 and 2) or moderate (class 3) CKD.
Another limitation of our study includes the retrospec-
tive nature of the study leading to potential observational
and selection biases. Important predictors of perioperative
and late outcomes, such as the urgency, the degree and
severity of tissue loss, and infection severity, were not eval-
uated and might have affected results and conclusions. It is
likely, given the profound effect of severe CKD on late
outcomes, that inclusion of such details would have
provided for more granular risk adjustment. The indica-
tions for intervention, variable preoperative workup, inter-
ventional technique, variable follow-up protocols, and the
timing and indication for major amputation were at the
discretion of the operating surgeon in the context of
routine medical care. These factors might have affected
periprocedural reintervention and late amputation rates,
however, without driving the outcomes in a speciﬁc direc-
tion for cause bias.
Other observational biases inherent to our study relate
to our tertiary medical center. Our cohort consisted of
patients referred into our system who might have under-
gone late follow-up with their referring physicians;
indeed, 40 patients (4.5%) were lost after the procedure
and 90 (10%) were monitored for <1 year. Because our
exposure of analysis was CKD severity, it is plausible
that severe CKD patients, who are generally sicker, may
have decided to follow-up locally. As a result, our late
reintervention and amputation rates might be higher
than those reported here. Patients lost to follow-up
were likely to have amputation risk of 7% to 20% long-
term based on the patients followed up at our institution.
Inclusion of 5 to 20 more amputations for late follow-up
would have added to the power of our Cox modeling but
not likely affected study conclusions. Our primary
outcome measure of perioperative and late mortality was
not subject to such observational bias, because all
mortality data were veriﬁed using the Social Security
Death Index, which remains reliable and valid indepen-
dent of location or cause of death (>99% survival
follow-up; n ¼ 877).
Given that all of our patients were included after a PVI
for infrainguinal PVD, there is an inherent selection bias in
our study. Patients with worse comorbidities, diminished
functional status, more advanced disease, and poor overall
prognosis may not have been referred for intervention;
obviously, those treated with primary amputation were
not considered. It is difﬁcult to speculate what the results
would have been if all eligible patients with severe CKD
and infrainguinal PVD underwent PVIs; however, the
direction of bias would likely be away from the null.
Despite these limitations, ours is the largest series to date
reporting on the effect of CKD after PVIs for infrainguinal
disease. Furthermore the study was likely adequately pow-
ered to detect the differences reported because outcomes
were fairly evenly distributed in sufﬁcient numbers across
the study groups.CONCLUSIONS
Our data concur with contemporary literature high-
lighting a strong negative impact of severe CKD in the
postoperative period (reintervention) and on late follow-
up (amputation, death, and death/amputation) after
infrainguinal PVIs. This risk is independent of age and clin-
ical presentation. Our study shows that even with inclusion
of patients with less advanced PVD (w30% claudicant
patients), severe CKD patients do not meet 1-year OPG
targets11 for survival (80% OPG vs 69% severe CKD in
our data). The presently reported rate of 69% would also
likely have been much lower had our cohort consisted
comprised completely of patients with rest pain or tissue
loss because CLI is also a major independent predictor26,27
of late mortality.
These ﬁndings suggest that presence of severe CKD
should be considered an important independent clinical
risk factor for, in particular, late adverse events. Further-
more, current guidelines, as deﬁned by the SVS OPGs,
may benchmark survival outcomes at levels unattainable
in patients with severe CKD.
AUTHOR CONTRIBUTIONS
Conception and design: VP, RC
Analysis and interpretation: VP, SM, JG, MC, MW, CK,
GL, RC
Data collection: JG
Writing the article: VP, RC
Critical revision of the article: VP, SM, MC, MW, CK, GL,
RC
Final approval of the article: VP, SM, JG, MC, MW, CK,
GL, RC
Statistical analysis: VP, SM
Obtained funding: Not applicable
Overall responsibility: VP
REFERENCES
1. Goodney PP, Beck AW, Nagle J, Welch HG, Zwolak RM. National
trends in lower extremity bypass surgery, endovascular interventions,
and major amputations. J Vasc Surg 2009;50:54-60.
2. LaMuraglia GM, Conrad MF, Chung T, Hutter M, Watkins MT,
Cambria RP. Signiﬁcant perioperative morbidity accompanies
contemporary infrainguinal bypass surgery: an NSQIP report. J Vasc
Surg 2009;50:299-304.
3. Conte MS, Geraghty PJ, Bradbury AW, Hevelone ND, Lipsitz SR,
Moneta GL, et al. Suggested objective performance goals and clinical
trial design for evaluating catheter based treatment of critical limb
ischemia. J Vasc Surg 2009;50:1462-73.
4. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Seely L, Lorenz TJ,
et al; PREVENT III Investigators. Results of PREVENT III: a multi-
center, randomized trial of edifoligide for the prevention of vein graft
failure in lower extremity bypass surgery. J Vasc Surg 2006;43:742-51.
5. Nehler MR, Brass EP, Anthony R, Dormandy J, Jiao J, McNamara TO,
et al; Circulase investigators. Adjunctive parenteral therapy with
lipo-ecraprost, a prostaglandin E1 analog, in patients with critical
limb ischemia undergoing distal revascularization does not improve
6-month outcomes. J Vasc Surg 2007;45:953-60.
6. Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF,
et al; BASIL trial participants. Bypass versus angioplasty in severe
ischaemia of the leg (BASIL): multicentre, randomised controlled trial.
Lancet 2005;366:1925-34.
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 2 Patel et al 3757. Ramdev P, Rayan SS, Sheahan M, Hamdan AD, LoGerfo FW,
Akbari CM, et al. A decade experience with infrainguinal revasculari-
zation in a dialysis-dependent patient population. J Vasc Surg 2002;36:
969-74.
8. Lantis JC, Conte MS, Belkin M, Whittemore AD, Mannick JA,
Donaldson MC. Infrainguinal bypass grafting in patients with end-
stage renal disease: improving outcomes? J Vasc Surg 2001;33:1171-8.
9. Owens CK, Ho KJ, Kim S, Schanzer A, Lin J, Matros E, et al.
Reﬁnement of survival prediction in patients undergoing lower
extremity bypass surgery: stratiﬁcation by chronic kidney disease clas-
siﬁcation. J Vasc Surg 2007;45:944-52.
10. Willenberg T, Baumann F, Eisenberger U, Baumgartner I, Do DD,
Diehm N. Impact of renal insufﬁciency on clinical outcomes in patients
with critical limb ischemia undergoing endovascular revascularization.
J Vasc Surg 2010;51:1419-24.
11. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney
disease and the risks of death, cardiovascular events, and hospitaliza-
tion. N Eng J Med 2004;351:1296-305.
12. Dormandy JA, Rutherford RB. Management of peripheral arterial
disease (PAD). TASC working group. Trans Atlantic Inter-Society
Consensus (TASC). J Vasc Surg 2000;31:S1-296.
13. K/DOQI clinical practice guidelines for chronic kidney disease: eval-
uation, classiﬁcation, and stratiﬁcation. Am J Kidney Dis 2002;
39(2 Suppl 1):S1-266.
14. Aulivola B, Gargiulo M, Bessoni M, Rumolo A, Stella A. Infrapopliteal
angioplasty for limb salvage in the setting of renal failure: do results
justify its use? Ann Vasc Surg 2005;19:762-8.
15. Brosi P, Baumgartner I, Silvestro A, Do DD, Mahler F, Triller J, et al.
Below the knee angioplasty in patients with end stage renal disease.
J Endovasc Ther 2005;12:704-13.
16. Conrad MF, Cambria RP, Stone DH, Brewster DC, Kwolek CJ,
Watkins MT, et al. Intermediate results of percutaneous endovascular
therapy of femoropopliteal occlusive disease: a contemporary series.
J Vasc Surg 2006;44:762-9.
17. O’Hare AM, Sidawy AN, Feinglass J, Merine KM, Daley J, Khuri S,
et al. Inﬂuence of renal insufﬁciency on limb loss and mortality after
initial lower extremity surgical revascularization. J Vasc Surg 2004;39:
709-16.
18. Simons JP, Goodney PP, Nolan BW, Cronenwett JL, Messina LM,
Schanzer A, on behalf of the Vascular Study Group of Northern NewEngland. Failure to achieve clinical improvement despite graft patency
in patients undergoing infrainguinal lower extremity bypass for critical
limb ischemia. J Vasc Surg 2010;51:1419-24.
19. Goodney PP, Nolan BW, Schanzer A, Eldrup-Jorgensen J, Bertges DJ,
Stanley AC, et al; for the Vascular Study Group of Northern New
England. Factors associated with amputation or graft occlusion one
year after lower-extremity bypass in Northern New England. Ann Vasc
Surg 2010;24:57-68.
20. The United States Renal Data system. Available at: www.usrds.org.
Accessed November 20, 2012.
21. Schanzer A, Mega J, Meadows J, Samson RH, Bandyk DF, Conte MS.
Risk stratiﬁcation in critical limb ischemia: derivation and validation of
a model to predict amputation-free survival using multicenter surgical
outcomes data. J Vasc Surg 2008;48:1464-71.
22. Goodney PP, Nolan BW, Schanzer A, Eldrup-Jorgensen J, Stanley AC,
Stone DH, et al; for the Vascular Study Group of Northern New
England. Factors associated with death 1 year after lower extremity
bypass in Northern New England. J Vasc Surg 2007;45:536-42.
23. Albers M, Romiti M, DeLuccia N, Brochado-Neto FC, Nishimoto I,
Pereira CA. An updated meta-analysis of infrainguinal arterial recon-
struction in patients with end-stage renal disease. J Vasc Surg 2010;51:
71-9.
24. Korhonen M, Biancari F, Soderstrom M, Arvela E, Halmesmaki K,
Alback A, et al. Femoropopliteal balloon angioplasty vs. bypass surgery
for CLI: a propensity score analysis. Eur J Vasc Endovasc Surg
2011;41:378-84.
25. Bradbury AW, Adam DJ, Bell J, Forbes JF, Fowkes FG, Gillespie I,
et al; BASIL Trial Participants. Bypass versus Angioplasty in Severe
Ischaemia of the Leg (BASIL) trial: a survival prediction model to
facilitate clinical decision making. J Vasc Surg 2010;51:52-68S.
26. Nasr MK, McCarthy RJ, Budd JS, Horrocks M. Infrainguinal bypass
graft patency and limb salvage rates in critical limb ischemia: inﬂuence
of mode of presentation. Ann Vasc Surg 2003;17:1992-7.
27. Arvela E, Soderstrom M, Korhonen M, Halmesmaki K, Alback A,
Lepantalo M, et al. Finnvasc score and modiﬁed Prevent III score
predict long-term outcome after infrainguinal surgical and endovas-
cular revascularization for critical limb ischemia. J Vasc Surg 2010;52:
1218-25.
Submitted Nov 20, 2012; accepted Sep 4, 2013.
